## **Supplementary Table 1. Details of Prospective Cohorts included in the Present Analyses**

Study	Study description	Year of inceptio	Participants	Number with blood	Years of Blood	Follow-up Years
		n		samples	Collection	Tears
Physicians' Health	Randomized	1982	22,071 male physicians, aged	15,124	1982-1984	20.8
Study I (PHS I)	clinical trial of		40-84 in 1982, free of prior			
	aspirin and beta-		CVD or cancer.	1,218	1996-1998	8.3
	carotene					
Physicians' Health	Randomized	1997	14,641 male physicians, aged	$11,133^{\dagger}$	1995-2002	8.4
Study II (PHS II)	clinical trial of		>=50 years, including 7,641			
	antioxidants and		PHS I and 7,000 new			
	multivitamin		participants.			
Nurses' Health	Prospective cohort	1976	121,700 female registered	32,826	1989-1990	16.4
Study (NHS)	study		nurses, aged 30-55 in 1976			
Health Professionals	Prospective cohort	1986	51,529 male health	18,018	1993-1994	10.5
Follow-up Study	study		professionals, aged 40-75 in			
(HPFS)			1986			
Women's Health	Randomized	1992	39,876 female health	28,345	1993-1996	10.6
Study (WHS)	clinical trial of		professionals, aged 40 or older			
	aspirin and vitamin		in 1992, free of prior CVD or			
	Е		cancer			
Women's	Randomized	1996	8,171 female health	5,922	1993-1996	9.0
Antioxidant	clinical trial of		professional aged 40 or older			
Cardiovascular	antioxidants and B-		with CVD or at least three			
Study (WACS)	vitamins		coronary risk factors			

<sup>†</sup> Of these, 6,518 blood samples are from men who have not previously donated a blood sample in PHS I

## Supplemental Table 2: Relationship between coronary heart disease risk factors at baseline and rs10757274 genotypes in controls

## rs10757274

	GG	AG	AA	P-Value
Age (years +/sd)	64.6 (9.3)	63.6 (9.4)	64.7 (8.9)	0.86
Sex (Women/Men) n,%	114 (32.5 %)	278 (37.1 %)	133 (37.1 %)	0.21
History of CVD n,%	101 (28.8 %)	177 (23.6 %)	85 (23.7%)	0.12
Hypertension n,%	138 (39.3 %)	290 (38.8 %)	136 (38.1 %)	0.74
Hypercholesterolemia n,%	147 (42.9 %)	306 (41.9 %)	129 (36.5 %)	0.09
Parental History of MI n,%	59 (16.8 %)	113 (15.1 %)	42 (11.7 %)	0.05
Diabetes n,%	18 (5.21%)	49 (6.5 %)	34 (9.5 %)	0.02
Body Mass Index: (kg/m2) (SD)	25.7 (4.5)	25.7 (3.8)	26.0 (4.4)	0.34

**Supplementary Table 3. Association of sudden cardiac death with correlated 9p21 variant rs2383207.** Shown are the odds ratios (95% CI) for increasing copy of the G allele of rs2383207 from conditional logistic regression models under an additive model.

Cohort	Case/ control	rs2383207				
		n	Frequency of G Allele	OR per G Allele (95% CI)	P-value	
HPFS	case	110	0.614	1.58	0.005	
HPFS	control	331	0.546	(1.15-2.14)		
PHS I	case	131	0.565	1.08	0.60	
PHS I	control	387	0.541	(0.81 - 1.44)		
PHS II	case	75	0.540	1.02	0.92	
PHS II	control	218	0.534	(0.70- 1.50)		
NHS	case	107	0.575	1.25	0.17	
NHS	control	321	0.527	(0.90- 1.74)		
WACS	case	35	0.529	1.19	0.53	
WACS	control	105	0.481	(0.70- 2.02)		
WHS	case	38	0.513	1.42	0.20	
WHS	control	107	0.439	(0.83 - 2.43)		
Meta-analysis	case	496	0.568	1.23 (1.06 - 1.43)	0.005	
Meta-analysis	control	1469	0.521	,		